Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer.
The long noncoding RNA H19 is overexpressed in many cancers and acts as an oncogene. Here, we investigated the role of H19 in thyroid carcinogenesis and its relation to microRNA miR-17-5p and its target gene YES1. H19 expression was higher in tumor samples and in thyroid cancer cell lines than nontumor tissues and normal thyroid cells. H19 knockdown and ectopic expression in the TPC-1 and NIM thyroid cancer cell lines showed that overexpression of H19 promoted proliferation, migration, and invasion, whereas H19 knockdown reduced cell viability and invasion and induced growth arrest in vitro and in vivo. H19 was identified as a target of miR-17-5p, by Dual-Luciferase Reporter assays and RNA-binding protein immunoprecipitation assays. H19 antagonized the function of miR-17-5p on upregulation of its target YES1 and inhibited miR-17-5p-induced cell cycle progression. Our results suggest that H19 functions as a competitive endogenous RNA (ceRNA) by acting as a sink for miR-17-5p, revealing a potential ceRNA regulatory network involving H19 and miR-17-5p with a role in the modulation of YES1 expression. This mechanism may contribute to a better understanding of thyroid cancer pathogenesis and provide new insights into the treatment of this disease.
Department of Nuclear Medicine, Shanghai Tenth people's hospital, Tongji university, Shanghai, China.|Department of institution of Interventional and Vascular surgery, Tongji university, Shanghai, China.
Lin
L
Liu
Department of Nuclear Medicine, Changhai hospital, The Second Military Medical University, Shanghai, China.
Jian
J
Yang
Department of Nuclear Medicine, Shanghai Tenth people's hospital, Tongji university, Shanghai, China.
Xuchao
X
Zhu
Department of Nuclear Medicine, Shanghai Tenth people's hospital, Tongji university, Shanghai, China.
Dan
D
Li
Department of Nuclear Medicine, Shanghai Tenth people's hospital, Tongji university, Shanghai, China.
Zhongwei
Z
Lv
Department of Nuclear Medicine, Shanghai Tenth people's hospital, Tongji university, Shanghai, China.|Department of institution of Interventional and Vascular surgery, Tongji university, Shanghai, China.
Xiaoping
X
Zhang
D063646:Carcinogenesis / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D055785:Gene Knockdown Techniques; D006801:Humans; D035683:MicroRNAs / Q000096:biosynthesis* / Q000235:genetics; D051575:Proto-Oncogene Proteins c-yes / Q000096:biosynthesis* / Q000235:genetics; D062085:RNA, Long Noncoding / Q000235:genetics*; D013964:Thyroid Neoplasms / Q000235:genetics* / Q000473:pathology
C094335:H19 long non-coding RNA; C524941:MIRN17 microRNA, human; D035683:MicroRNAs; D062085:RNA, Long Noncoding; D051575:Proto-Oncogene Proteins c-yes; C489834:YES1 protein, human
H19; YES1; competing endogenous RNA; long noncoding RNA; microRNA-17-5p; thyroid cancer